PTGDR and hepatocellular carcinoma: Based on the data obtained from the RHWU Cohort, the combination of exosomal LUCAT‐1, exosomal EGFR‐AS‐1, serum AFP, and serum DCP effectively differentiated healthy individuals from patients with HCC (Figure 4O) and displayed superior characteristics (Figure S7 and Table S4, Supporting Information).